339 The 3-Year Outcome of Optimal Medical or Surgical Management of GERD Patients with Barrett's Esophagus: the Lotus Trial Experience

Stephen E. Attwood(Durham University), Tore Lind(Skaraborg Hospital), Ola Junghard(AstraZeneca (Sweden)), Jan Gunnar Hatlebakk, Christian Ell(Johannes Gutenberg University Mainz), Lars Lundell(Karolinska Institutet), Stefan Eklund(AstraZeneca (Sweden)), Jean Paul Galmiche(Centre Hospitalier Universitaire de Nantes), Roberto Fiocca(Alleanza Contro il Cancro)

Gastroenterology

April 1, 2008

10.1016/s0016-5085(08)63951-7

Cited by 1

Related Papers

Esophageal eosinophilia with dysphagia

|Digestive Diseases and Sciences|1993|889

Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study

|Helicobacter|1996|575

A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop1 1Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epidemiology. Conference chairman: Prateek Sharma; conference moderator: Kenneth McQuaid; group leaders: John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler; participants: Alan Cameron, Douglas Corley, Gary Falk, John Goldblum, John Hunter, Janusz Jankowski, Lars Lundell, Brian Reid, Nicholas Shaheen, Amnon Sonnenberg, Kenneth Wang, and Wilfred Weinstein.

|Gastroenterology|2004|526

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

|Gastroenterology|1999|433

Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process

|Gastroenterology|2012|378